After an afternoon of vigorous debate, members of the Oncologic Drugs Advisory Committee (ODAC) endorsed, by a 15-1 margin, the benefit/risk profile for peginesatide injection to treat anemia associated with chronic kidney disease (CKD) in adult patients on dialysis.